Elan reports pre-tax loss of $88.6m for the first quarter of 2009; Tysabri sales up 48%
Apr 22nd, 2009 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan today reported a pre-tax loss of $88.6m for the first quarter of 2009, an increase on the pre-tax loss figure of $83.4m for the same time last year. Revenues rose by 14% to $245.1m from $214.7m mainly as a result of a strong performance from Elan's multiple sclerosis drug Tysabri. This offset reduced sales of its Azactam and Maixpime drugs. Sales of the MS drug Tysabri rose by 48%.
